• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp. (Amendment)

    2/14/24 4:00:26 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNXP alert in real time by email
    SC 13G/A 1 o1172412sc13ga2.htm AMENDMENT NO. 2

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Tonix Pharmaceuticals Holding Corp.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

     

    890260854

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    Page 1 of 8
     

     

    CUSIP No. 890260854 

     

    13G/A Page 2 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0% 

    12

    type of reporting person

     

    pN 

     

    Page 2 of 8
     

     

    CUSIP No. 890260854 13G/A Page 3 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0% 

    12

    type of reporting person

     

    OO 

     

    Page 3 of 8
     

     

    CUSIP No. 890260854

     

    13G/A Page 4 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (
    b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    UNITED STATES

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0% 

    12

    type of reporting person

     

    IN 

     

    Page 4 of 8
     

     

    Item 1(a).Name of Issuer:

     

    Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    26 Main Street, Chatham, NJ 07928

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP Number: 890260854

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    Page 5 of 8
     

     

    (b)Percent of Class:

     

    Tang Capital Partners 0.0%
    Tang Capital Management 0.0%
    Kevin Tang 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)      sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       

    (ii)     shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       

    (iii)     sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       

    (iv)    shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Page 6 of 8
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 8
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

     

     

    Get the next $TNXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNXP

    DatePrice TargetRatingAnalyst
    4/18/2022Outperform
    Noble Capital Markets
    More analyst ratings

    $TNXP
    SEC Filings

    See more
    • SEC Form 8-K filed by Tonix Pharmaceuticals Holding Corp.

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      5/8/25 5:16:06 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/29/25 4:08:13 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/25/25 4:59:30 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

      Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company's presentation is available under the Scient

      4/29/25 9:05:04 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

      TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an

      4/24/25 7:55:30 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

      CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress website here. Presentati

      4/16/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Tonix Pharma

      Noble Capital Markets initiated coverage of Tonix Pharma with a rating of Outperform

      4/18/22 9:20:45 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners resumed coverage on Tonix Pharmaceuticals with a new price target

      Alliance Global Partners resumed coverage of Tonix Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.00 previously

      2/25/21 7:39:46 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Financials

    Live finance-specific insights

    See more
    • Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

      Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), Indicated for the Treatment of Acute Migraine in Adults, Complements Tonix's Current Intranasal Clinical Development Program of TNX-1900 for Migraine Prevention CHATHAM, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it

      7/3/23 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

      Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study and Phase 2 Long COVID Study Expected Second Quarter 2023 Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. Operational Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022 CHATHAM, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the

      11/7/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

      The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company's 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix's Advanced Development Center (ADC) for acce

      6/16/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Leadership Updates

    Live Leadership Updates

    See more
    • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonst

      3/18/25 4:30:00 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

      Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia CHATHAM, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadershi

      1/8/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

      Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Errol Gould, Ph.D., joins Tonix as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025 If

      12/3/24 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bell Margaret Smith disposed of $0 worth of shares (1 units at $0.15), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:32:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Treco James disposed of $0 worth of shares (0 units at $0.30), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:48 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Olukotun Adeoye Y disposed of $2 worth of shares (1 units at $1.91), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:25 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care